Sector News

Biogen appoints Mark Hernon as SVP, Chief Information Officer

December 5, 2017
Life sciences

Biogen announced today the appointment of Mark Hernon as Senior Vice President, Chief Information Officer, effective December 4.

In his new role, Mr. Hernon will lead the global information technology (IT) organization and be responsible for accelerating and supporting Biogen’s operations through delivery of innovative technology capabilities, systems, and tools that align with Biogen’s corporate strategy. Mr. Hernon joins Biogen with more than 30 years of experience in IT and strategic leadership. In recent years with Takeda Pharmaceuticals, he was the Regional CIO for the Americas and Global Head of R&D, QA and HR Systems, as well as VP of Operations for the Cambridge, MA site. He was most recently the Global Head of R&D Site Strategy and Operations, where he led the global transformation of Takeda’s R&D footprint.

“With Mark’s years in industry successfully leading global IT and operations functions, we are extremely pleased to have him join us at Biogen,” said Ms. Alexander. “His experience and leadership together with our existing excellent Biogen IT organization will allow Biogen to continue creating and harnessing data and information to pioneer new developments in neuroscience.”

Prior to his role with Takeda, Mr. Hernon spent 12 years with Millennial Pharmaceuticals as CIO and VP Operations, leading strategic initiatives to streamline the organization, aligning with the business, and managing the group’s transition through the acquisition by Takeda.

“I am excited at the prospect of leading a team of talented and dedicated individuals focused on enabling Biogen’s strategy through the smart application of technology,” said Mr. Hernon.

Mr. Hernon holds a BS and MS in Industrial and Management Engineering from Rensselaer Polytechnic Institute, and an MBA from the Lally School of Management at Rensselaer Polytechnic Institute.

Source: Biogen

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach